Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer’s meningitis B vaccine Trumenba launches in UK

Pfizer’s meningitis B vaccine Trumenba launches in UK

12th July 2017

Pfizer has announced the launch of its new meningitis B vaccine Trumenba in the UK.

The drug is to be made available for the active immunisation of individuals aged ten and above to prevent invasive meningococcal disease caused by meningococcal group B bacteria.

This vaccine was first approved in Europe in May after clinical trials involving more than 20,000 adolescents and adults showed that it induced protective serum bactericidal antibody responses to a range of test strains, as well as showing an acceptable safety profile.

Pfizer will now look to work with the UK's Joint Committee on Vaccination and Immunisation and the Department of Health to discuss an approach to providing greater access to the vaccine via the National Immunisation Programme.

Dr Tom Nutt, chief executive of UK charity Meningitis Now, welcomed the launch of the product, saying: "The licensing of Trumenba marks another victory in our battle against meningitis and it takes us another step closer to fulfilling our mission where no-one in the UK dies from the disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801837763-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.